Preventing Diabetes.

Our Medical Device: SiPore15^TM

SiPore15™ is a breakthrough medical device for the safe reduction of blood sugar levels in people at risk of developing diabetes, prediabetics, and newly diagnosed type 2 diabetics. The device is a tasteless and odourless white powder taken with water. Upon its approval, SiPore15™ will be the first non-systemic therapy for prediabetes, with the potential to prevent type 2 diabetes.

SiPore15™ is Sigrid Therapeutics’ lead product candidate in clinical development, originating from research at Stockholm University and Karolinska Institutet.

About Us

Lifestyle diseases, caused by poor diet and physical inactivity among others, are rising rapidly worldwide. Each year, 70% of all deaths globally – 40 million – are attributed to lifestyle diseases such as obesity, type 2 diabetes and heart disease.

Sigrid is a clinical-stage biotech Company driven by the vision to improve human health through material based innovations. We are pioneering a new class of engineered materials to prevent and treat lifestyle disease more safely than existing solutions on the market.

Clinical Trials

SiPore15^TM is currently being evaluated in a Proof of Concept clinical trial in prediabetics and newly diagnosed type 2 diabetics in a multicenter trial in Europe (ClinicalTrials.gov Identifier: NCT03823027). The trial has completed full enrollment and topline results will be reported in the fourth quarter of 2019.